From: Ankylosing Spondylitis News By: Patricia Inacio, PhD. According to Spherix Global Insights' survey, which was conducted in March, the main barriers to prescribing Cimzia for nr-axSpA in the U.S. were insurance and cost issues. However, the number of rheumatologists citing these as obstacles has significantly decreased year after year, which highlights the potential widespread use for Cimzia...(read more).
From: Multiple Sclerosis News Today By: Marta Figueiredo Prescriptions of Roche's Ocrevus (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching a disease-modifying therapy (DMT) continue to rise in Europe, according to a survey conducted by Spherix Global Insights...(read more)
A recent survey by Spherix Global Insights showed that one-quarter of neurologists are less likely to prescribe a migraine therapy that has been on the market for less than a year due to the ongoing COVID-19 crisis
From: FiercePharma By: Beth Snyder Bulik AbbVie Prompts Patients to 'take on' Arthritis in First Rinvoq DTC Ad While Xeljanz still enjoys support from rheums given the drug’s seven-year commercial history, docs indicated Rinvoq as the most preferred JAK if only one were to be prescribed, citing safety, efficacy and breadth of data all as key advantages over Xeljanz," Piper Jaffray analyst Christopher Raymond wrote...(read more).
From: Multiple Sclerosis News Today By: Ana Pena, PHD. Ocrevus Use Rises Among New Starters with RRMS, Loses Ground to Other Therapies in PPMS First-line use of Genentech's Ocrevus (ocrelizumab) for patients with multiple sclerosis (MS) has remained stable through 2019 compared to 2018, according to the latest Spherix Global Insights' report...(read more).
From: FiercePharma By: Kyle Blankenship AbbVie's Rinvoq Continues March with NICE Nod in Rheumatoid Arthritis In December, a rheumatologist survey conducted by Spherix Global Insights showed about half of 100 physicians would prescribe Rinvoq over other JAK inhibitors, specifically citing AbbVie's "stewardship" of the drug as a positive for prescribing, Piper analyst Christopher Raymond said in a note to investors...(read more).